SPOP mutation leads to genomic instability in prostate cancer

Genomic instability is a fundamental feature of human cancer often resulting from impaired genome maintenance. In prostate cancer, structural genomic rearrangements are a common mechanism driving tumorigenesis. However, somatic alterations predisposing to chromosomal rearrangements in prostate cancer remain largely undefined. Here, we show that SPOP, the most commonly mutated gene in primary prostate cancer modulates DNA double strand break (DSB) repair, and that SPOP mutation is associated with genomic instability. In vivo, SPOP mutation results in a transcriptional response consistent with BRCA1 inactivation resulting in impaired homology-directed repair (HDR) of DSB. Furthermore, we found that SPOP mutation sensitizes to DNA damaging therapeutic agents such as PARP inhibitors. These results implicate SPOP as a novel participant in DSB repair, suggest that SPOP mutation drives prostate tumorigenesis in part through genomic instability, and indicate that mutant SPOP may increase response to DNA-damaging therapeutics. DOI: http://dx.doi.org/10.7554/eLife.09207.001

[1]  Long Yu,et al.  Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants , 2014, Cell reports.

[2]  K. A. Gelmon.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[3]  D. Zheng,et al.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.

[4]  P. Carroll,et al.  Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.

[5]  M. Rubin,et al.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover , 2013, Proceedings of the National Academy of Sciences.

[6]  K. Knudsen,et al.  Transcriptional Roles of PARP1 in Cancer , 2014, Molecular Cancer Research.

[7]  K. Rajapakshe,et al.  Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. , 2014, Cancer research.

[8]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[9]  Alessandro Romanel,et al.  Unraveling the clonal hierarchy of somatic genomic aberrations , 2014, Genome Biology.

[10]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[11]  Bo Xu,et al.  Speckle-type POZ protein, SPOP, is involved in the DNA damage response. , 2014, Carcinogenesis.

[12]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[13]  M. Gerstein,et al.  Distinct genomic aberrations associated with ERG rearranged prostate cancer , 2009, Genes, chromosomes & cancer.

[14]  T. Visakorpi,et al.  Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. , 1995, Cancer research.

[15]  S. Carr,et al.  Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer , 2014, Science.

[16]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[17]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[18]  H. Hieronymus,et al.  SPOP mutations in prostate cancer across demographically diverse patient cohorts. , 2014, Neoplasia.

[19]  Chris Sander,et al.  Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.

[20]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[21]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[22]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[23]  Hongjuan Zhao,et al.  Genome‐wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines , 2005, The Prostate.

[24]  E. Cuppen,et al.  Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures , 2014, Cell.

[25]  O. Witte,et al.  Isolation, cultivation and characterization of adult murine prostate stem cells , 2010, Nature Protocols.

[26]  L. Thompson,et al.  XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. , 1999, Genes & development.

[27]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[28]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[29]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[30]  Yan Tang,et al.  Destruction of DDIT3/CHOP Protein by Wild‐Type SPOP but Not Prostate Cancer‐Associated Mutants , 2014, Human mutation.

[31]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[32]  Igor Jurisica,et al.  Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. , 2014, The Lancet. Oncology.

[33]  Stéphanie Panier,et al.  Double-strand break repair: 53BP1 comes into focus , 2013, Nature Reviews Molecular Cell Biology.

[34]  D. Mittelman,et al.  DNA end joining becomes less efficient and more error-prone during cellular senescence. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[36]  P. Baumann,et al.  Human Rad51 Protein Promotes ATP-Dependent Homologous Pairing and Strand Transfer Reactions In Vitro , 1996, Cell.

[37]  W. Huttner,et al.  Brca1 is required for embryonic development of the mouse cerebral cortex to normal size by preventing apoptosis of early neural progenitors , 2009, Development.

[38]  Jianfeng Xu,et al.  Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array , 2006, Genes, chromosomes & cancer.